Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.
|
|
- Millicent Phillips
- 6 years ago
- Views:
Transcription
1 Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. To aid the management and treatment of Parkinson s Patients with compromised swallow and those nil by mouth. AUTHORS: Alison Waldron (Acute Clinical Nurse Specialist in Parkinson s disease) Steven Shanu (Resident Pharmacist) Sarah Baig (Medicines Information/Neurology Directorate Pharmacist) Dr. Janine Barnes (Neurology Specialist Pharmacist) Dr. Shams Duja (Consultant in Elderly Care) Dr. Alistair Lewthwaite (Consultant Neurologist) Trudy Gaskin (Community Clinical Nurse Specialist in Parkinson s disease) VERSION CONTROL June This is a new document August 2014 Consultation with GPs (primary care) Dr Bowen, Dr Martin Consultation with consultants (secondary care) Dr Michael Dr Stellman Dr McGrath Dr Ijaola Dr Lewthwaite Dr Douglas Review of document version 1.1 December 2014 Version 1.1 Circulated to GP s PBP s DGNHSFT Consultants DGNHSFT Nurses Dudley CCG Dudley MBC NOC Project Support CCG Head of Commissioning
2 A translation service is available for this document. The Interpretation/Translation Policy, Guidance for Staff is located on the intranet under Trust-wide Policies. Contents Section Page Number 1 Introduction 3 2 Statement of Intent 3 3 Scope 3 4 Definitions 3 5 Duties & Responsibilities 3 6 Consequences of missing Parkinson s medicines Parkinsons disease management in patients Secondary 4 care 7.1a) Patients with a compromised swallow or nil by mouth in 4 secondary care 7.1b) Hospital Surgery/NG patients (flow chart) a) Community Palliative or end of life care patients (flow 5 chart) 8.0 Nasogastric administration of Levodopa and Dopamine 6-7 Agonist 9.0 Conversion table for Transdermal delivery Drugs to avoid in Parkinson s Disease Apomorphine Guidelines Contact Details References and Acknowledgements 8-9 Appendix 1 Common oral medicines used in Parkinson s Disease 10 Appendix 2 Commonly used drugs to avoid in Parkinson s Disease 11 Appendix 3 Conversion Algorithm 12 Appendix 4 Conversion charts 13 Appendix 5 Review and monitoring adherence to guideline 14
3 1. INTRODUCTION Clinical experience and audit has revealed that Parkinson s patients who are NBM or experience swallowing difficulties are experiencing lack of consistency in their prescribing of medication. This guideline aims to standardise treatment with respect to appropriate timings, doses and formulations for patients. 2. STATEMENT OF INTENT This document is designed to rationalise the prescribing in this patient group. There is an intention to meet individual patient needs and involve the patient and their family/carers in discussions and decisions about their medication and prescribing. 3. SCOPE The Nurse Practitioners of Parkinson s disease are responsible for the day to day management of Parkinson s disease patients both in hospital and in the community. The Pharmacists are responsible for specialist advice on specific medicines management and appropriate use of dose calculators. The consultant lead and medical team is responsible for the day to day medical management of Parkinson s disease The Area Clinical Effectiveness Committee will oversee the ratification of the guideline and appropriate review. 4. DEFINITIONS CK Creatinine Kinase MAO-B Monoamine Oxidase B inhibitor NBM Nil by mouth NG Naso Gastric NMS Neuroleptic Malignant Syndrome PD Parkinsons Disease L-Dopa Levo-Dopa COMT Catechol-o-methyl Transferase 5. DUTIES & RESPONSIBILITIES For patients managed in primary care please contact Trudy Gaskin (community Parkinson s specialist nurse) or Dr Janine Barnes (Neurology Specialist Pharmacist). For secondary care patients please contact Alison Waldron (Acute Clinical Nurse Specialist in Parkinson s disease), Dr Shams Duja (Consultant in Elderly Care) or Dr Alistair Lewthwaite (Consultant Neurologist). Review and update of this guideline will take place every 3 years. 3
4 6. CONSEQUENCES OF MISSING PARKINSONS DISEASE DRUGS Medication is crucial in optimal management of Parkinson s. If medication is not given it can result in the deterioration in patients symptoms, including reduced swallow, risk of aspiration, speech problems, increased risk of falls and increased dependence on nursing staff. At worst it may develop into Neuroleptic Malignant Syndrome. Neuroleptic Malignant Syndrome Rare Due to sudden withdrawal of PD medication Hyperthermia, muscle rigidity, altered level of consciousness, autonomic instability and elevated serum creatinine kinase (CK) level Onset within 1 to 9 days Major complications are respiratory, renal and cardiovascular failure Carries significant mortality People with Parkinson s are admitted to hospital for many reasons, very often unrelated to their Parkinson s. However if this is not managed appropriately on admission it can lead to delayed recovery, delayed discharge and poor outcomes for patients and their families. 7.0 PARKINSONS DISEASE MANAGEMENT IN PATIENTS SECONDARY CARE 7.1A) PATIENTS WITH A COMPROMISED SWALLOW OR NIL BY MOUTH IN SECONDARY CARE (Adapted from the NHS Tayside Administration of Medicine in the Peri-operative Period) Many people with Parkinson s present to surgical specialties for the management of conditions unrelated to their Parkinson s. The decision to discontinue, or accidentally omit, medication pre-operatively can cause severe harm including inability to swallow, speak or move increasing the risk of aspiration pneumonia, falls and fractures. It can precipitate an acute withdrawal syndrome similar to Neuroleptic Malignant Syndrome which can be fatal. If possible levodopa treatment should be continued throughout the peri-operative period. Selegiline and Rasagiline are both Monoamine oxidase inhibitors (MAO-B) and can interact with anaesthetic agents. The COMT inhibitors Entacapone, Tolcapone and Stalevo (entacapone plus levodopa) can all interact with adrenaline, isoprenaline and noradrenaline. The anaesthetist should be informed. If prolonged surgery expected or if oral route is going to be compromised post-operatively it may be worthwhile converting patient to rotigotine patch pre-operatively. Discuss with Parkinson s nurse specialist but in an emergency the online conversion calculator can be used to switch to rotigotine patch. See online calculator Patients and their family/carers will be kept informed and are actively encouraged to be involved in matters pertaining to medication changes and the management of their condition. Note: bedside swallow test used by nurses on some wards is designed for stroke patients only. Swallow problems are very common in Parkinson s, particularly during an intercurrent illness.
5 7.1 b) HOSPITAL FLOW CHART If you think the patient s swallow is compromised follow the following algorithm: Contact Acute Clinical Nurse Specialist for Parkinson s disease Bleep 5026 Refer to Speech and Language therapy via Soarian If unable to contact Parkinson s Disease Specialist Nurse, continue through flow chart Hospital contact Alison Waldron Bleep 5026 (Acute Clinical Nurse Specialist in Parkinson s disease) Can the patient tolerate an NG tube? YES Follow NG administration guidelines (section 8) NO Convert to Rotigotine patch see Hub 7.2 a) COMMUNITY - PALLIATIVE OR END OF LIFE CARE PATIENTS Does patient qualify to be transferred to hospital for NG/PEG administration of medications (As per palliative care guidelines) Dr. Janine Barnes (Neurology Specialist Pharmacist) Trudy Gaskin Community Clinical Nurse Specialist in Parkinson s disease Contactable via Dudley Rehabilitation Service YES Transfer Patient to Hospital NO Convert To Rotigotine Transdermal patch Patients and their family/carers will be kept informed and are actively encouraged to be involved in matters pertaining to medication changes and the management of their condition. 5
6 PLEASE NOTE: CONVERSION BACK TO ORAL PD MEDICATION IS NOT ALWAYS APPROPRIATE. IF THIS IS REQUIRED THEN CONTACT THE RELEVANT PD NURSE (COMMUNITY OR HOSPITAL BASED) FOR ADVICE. 8. NASOGASTRIC ADMINISTRATION OF LEVODOPA AND DOPAMINE AGONIST On occasions it may be necessary to administer PD medications via an NG tube temporarily although these recommendations can be followed for long term enteral administration. Normal prescription Co-beneldopa (Madopar) Method of administration/alternative Madopar dispersible, same doses as tablets. CR formulations require a slight dose reduction mg benserazide + 50 mg levodopa. 25 mg benserazide mg levodopa. Tablets disperse in 10 ml of water within 2 minutes to give a cloudy white dispersion that flushes via an 8Fr NG tube without blockage Co-careldopa (Sinemet) Standard formulations disperse in water, alternatively convert to equivalent dose of dispersible co-beneldopa. Tablets disperse readily when placed in 10 ml of water to form a bright yellow dispersion that settles quickly but flushes via an 8Fr NG tube without blockage. Care must be taken to administer whole dose owing to the tendency for settlement to the bottom of the container/syringe. 2 CR formulations require a slight dose reduction. 1 Entacapone Stalevo (combination of co-beneldopa and entacapone) Resagiline Selegiline Sinemet (cocareldopa) Sinemet 62.5mg tablet Sinemet 110mg tablet Sinemet Plus 125mg tablet Sinemet 275mg tablet Half Sinemet CR 125mg tablet Sinemet CR 250mg tablet Madopar (Cobeneldopa) Madopar 62.5mg disp. tablet Madopar 125mg disp. tablet Madopar 125mg disp. tablet 2 x Madopar 125mg disp. tablet Convert to ordinary formulation dose Convert to ordinary formulation dose Disperses less easily Enteral tubes will need to be flushed well after use Give equivalent doses of co-beneldopa dispersible as above and entacapone as above.2 Contacted the manufacturer, unfortunately no information is available on crushing. Consider switch to selegiline if patient unable to swallow Zelapar ( melt (dissolves on the tongue) 1.25mg equivalent to 10mg selegiline If patient able to take buccal tablets, alternatively crush tablets. Syrup preparation 10mg/5ml (only for enteral tubes) 2
7 Amantadine Liquid available (50mg/5ml) for enteral tubes only Amantadine hydrochloride is freely soluble in water. 2 The capsules may be opened and mixed with water and administered immediately via an enteral feeding tube. 1,2 Ropinerole Ropinerole L Pramipexole Pramipexole PR (prolonged release) Maintain same doses Crush tablets. Tablets disintegrate rapidly when placed in 10 ml of water to give fine dispersion that flushes via an 8Fr NG tube without blockage. 1 Convert to standard ropinerole Crush as above Ropinirole Starter pack 1mg tds 2mg tds 3mg tds 4mg tds 6mg tds 8mg tds Controlled release Ropinirole (L) N/A 4mg/day 6mg/day 8mg/day 12mg/day 16mg/day 24mg/day Maintain same doses crush tablets and disperse in water 2 Convert to standard pramipexole Crush as above Pramipexole (salt content) 0.125mg tds 0.25mg tds 0.5mg tds 0.75mg tds 1mg tds 1.25mg tds 1.5mg tds Pramipexole (base content) 0.088mg tds 0.18mg tds 0.35mg tds 0.53mg tds 0.7mg tds 0.88mg tds 1.05mg tds 9. CONVERSION TO TRANSDERMAL DELIVERY (PATCH SYSTEM) VIA HUB 10. DRUGS TO AVOID IN PARKINSONS DISEASE For drugs to avoid in Parkinson s disease please refer to appendix APOMORPHINE PRESCRIBING/DISPENSING Under no circumstances should this be initiated without involvement with a Parkinson s specialist. 7
8 11. a) HOSPITAL If a patient is admitted on apomorphine please contact the PD nurse specialist as soon as possible. If urgent advice is needed out of hours there is a 24 hour Apo-go helpline available on Out of hours please contact the on-call pharmacist via switchboard. 11. b) COMMUNITY For any community queries regarding apomorphine please contact Trudy Gaskin or Janine Barnes via Dudley Rehabilitation Service ( ) or If urgent advice is needed out of hours there is a 24 hour Apo-go helpline available on CONTACT DETAILS Alison Waldron (Acute Clinical Nurse Specialist in Parkinson s disease), Dudley Group NHS Foundation Trust. Bleep 5026 Trudy Gaskin (Community Clinical Nurse Specialist in Parkinson s disease) / Dr Janine Barnes (Neurology Specialist Pharmacist) / REFERENCES AND ACKNOWLEDGEMENTS 1. Smyth J, editor. The NEWT Guidelines for administration of medication to patients with enteral feeding tubes or swallowing difficulties. Print version, 2 nd edition published Online version updated more frequently, available at (subscription required). 2. Handbook of Drug Administration via Enteral Feeding Tubes. Accessed via on 12 th March Cabergoline vs Pergolide vs Pramipexole vs Ropinirole. Grosset et al. Movement Disorders2004;19 (11): Ropinirole, Pramipexole, Cabergoline vs Rotigotine. Le Witt et al. Clinical Neuropharmacology2007; 30 (5): Ropinirole vs Requip L. Summary of product Characteristics, Requip L. Electronic Medicines Compendium. 6. Algorithm for estimating parenteral doses of drugs for parkinson s Disease. Brennan K, Genever R. BMJ 2010; Acute management of PD patients with compromised swallow or NBM. Formulated by PDNS North west.
9 8. Acute management of Parkinson s patients. NHS Fife NHS Tayside guide to the administration of medicines in the peri-operative period June NHS Dudley Parkinson s disease prescribing guidelines for use in primary and secondary care. Access via: Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care 9
10 Appendix 1 COMMON ORAL MEDICATIONS USED IN PARKINSON S DISEASE Type of Drug Drug Name How it Works Precautions Levodopa Co-careldopa Co-beneldopa Sinemet Madopar Dopamine Agonist Monoamine Oxidase type B (MAO-B) inhibitors COMT inhibitors Pramipexole Ropinerole Selegiline Rasagiline Entacapone Stalevo Anticholinergics Trihexyphendyl (Benzhexol) Glutamate Agonist Amantadine L-dopa is the precursor of dopamine. Can be used at all stages of the disease process. Works well on stiffness and Bradykinesia Stimulates post synaptic dopaminergic receptors Slows the metabolism of dopamine Blocks the metabolism of dopamine Blocks the action of acetylcholine (which breaks down dopamine) Enhances the release of dopamine. Anticholinergic properties Becomes less effective over time. Dyskinesia Drowsiness Hallucinations Postural Hypotension Nauses/vomiting Hallucinations Impulse Control Disorder Confusion Drug is a stimulant, therefore should be taken in the morning Will increase side effects of L-dopa Limited efficacy Neuro-psychiatric side effects Mild effect Short lived Insomnia
11 Appendix 2 COMMONLY USED DRUGS TO AVOID If patient already stabilised on therapy review and monitor Table highlighting drugs to avoid (and use) when treating hallucinations and nausea: Drug Chlorpromazine Treatment of Hallucinations /Confusion Treatment of Nausea / Vomiting Vigilance is required with the use of Fluphenazine Perphenazine Trifluoperazine Flupenthixol Haloperidol Quetiapine Clozapine (specialist initiation only) Metoclopramide Prochlorperazine Domperidone Cyclizine Ondansetron Antihistamines ¹ Antidepressants ¹ Antipsychotics ¹ Antihypertensives e.g Calcium Channel Blockers ¹ Key: x Not recommended Recommended ¹ Vigilance required 11
12 Appendix 3 CONVERSION ALGORITHM Algorithm for estimating equivalent levodopa dosages for Rotigotine patch This is the Parkinson s UK validated calculation tool for conversion of oral Parkinson s medications to transdermal patch. This has been incorporated into the online Rotigotine convertor. 1. Calculate Adjusted Levodopa Equivalent Daily Dose (LEDD): [(A) + (B)] x 0.55 = mg (A) Total adjusted daily levodopa dose. Total daily levadopa dose in mg (excluding benserazide or carbidopa). 0.7 (if MR/CR) or 1.3 (if on COMT inhibitor) or 0.91 (if MR/CR and on COMT inhibitor) = mg (B) Total adjusted daily dopamine agonist estimate levodopa equivalent dose Total daily dopamine agonist in mg 100 (if on pramipexole/ cabergoline/ pergolide 20 (if on ropinerole) 10 (if on bromocriptine/ apomorphine = mg (the above figures refer to each medications levodopa equivalent factor) 2. Calculate dosage for Rotigotine patch = Adjusted LEDD / 20 = mg Maximum Rotigotine dose of 8mg in 24hrs (for monotherapy) Maximum Rotigotine dose of 16mg in 24hrs (dual-therapy) Round to the nearest 2mg (max of 16mg) and prescribe as 24hr patch DO NOT CUT PATCH. Available as 1mg//2mg/3mg/4mg/6mg/8mg patches (can use more than one patch).
13 Appendix 4 CONVERSION CHARTS Conversion table for dopamine agonists Pramipexole (salt content) Pramipexole (base content) Ropinirole Controlled release Ropinirole Rotigotine patch 0.125mg tds 0.088mg tds Starter pack N/A 2mg/24 hrs 0.25mg tds 0.18mg tds 1mg tds 4mg/day 4mg/24hrs 0.5mg tds 0.35mg tds 2mg tds 6mg/day 6mg/24hrs 0.75mg tds 0.53mg tds 3mg tds 8mg/day 8mg/24hrs 1mg tds 0.7mg tds 4mg tds 12mg/day 10-12mg/24hrs 1.25mg tds 0.88mg tds 6mg tds 16mg/day 14mg/24hrs 1.5mg tds 1.05mg tds 8mg tds 24mg/day N/A Conversion table for levodopa Current levodopa regime (standard release) Co-beneldopa or co-careldopa 62.5 bd Co-beneldopa oe co-carel dopa 62.5 tds Co-beneldopa or co-careldopa 62.5 qds Co-beneldopa or co-careldopa 125 tds Co-beneldopa or co-careldopa 125 qds Rotigotine patch equivalent 2mg/24hrs 4mg/24hrs 6mg/24hrs 8mg/24hrs 10mg/24hrs Conversion table for Stalevo Current stalevo regime Rotigotine patch equivalent Dispersible co-beneldopa (May need to give smaller, more frequent dosing) 50/12.5/200 tds 6mg/24hrs 62.5mg qds 100/25/200 tds 10mg/24hrs 125mg qds 100/25/200 qds 14mg/24hrs 125 mg 5 times daily 150/37.5/200 tds 16mg/24hrs 125 mg 6 times daily 13
14 APPENDI 5 REVIEW AND MONITORING ADHERANCE TO GUIDELINES Lead Tool Frequency Reporting Arrangements Acting on recommendations and Lead(s) Change in practice and lessons to be shared Adherence to this guideline through actual and near miss incident reporting Inpatient Audit All Health Care Professionals Alison Waldron DATI Incident Reporting System Quarterly Audit Every 6 months Quarterly Aggregated Report of Incidents to the Clinical Quality Safety and Patient Experience Committee Report to Directorate Depending on Compliance, outcome and clinical or operational area Director Lead or Manager assigned. Depending on outcome Lead consultant will act Directorate Risk Management Groups
Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationAcute management of in-patient Parkinson s Disease patients
Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More informationCLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction The cause of Parkinson s symptoms The types of Parkinson s drugs used in MSA Finding the best medication Additional medication Drugs to avoid Further information An Overview of Parkinson s
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationAn Overview of Parkinson s Medication used in Multiple System Atrophy
Introduction Cause of Parkinson s symptoms Parkinson s drug use in MSA Finding the best medication Other medication - Interaction Drugs to avoid Further information An Overview of Parkinson s Medication
More informationParkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care
Parkinson's Disease Prescribing Guidelines for use in Primary and Secondary Care 2017 Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Document Description Document Type
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationGuideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017
Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017 1. INTRUCTION 1.1 Guideline for the management of Parkinson s Disease Medication in adult patients presenting to
More informationGUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:
GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL Record Type Clinical Guideline elibrary ID Reference No: CG 1813 Newly developed and approved Trust-wide Clinical
More informationMedicines Management and the Unwell Parkinson s Patient
Medicines Management and the Unwell Parkinson s Patient Belinda Kessel Geriatrician and Movement Disorder Specialist Princess Royal University Hospital Orpington, Kent The Society for Acute Medicine, 7
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationDorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE
SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationDr Alistair Lewthwaite Consultant Neurologist Dudley Group of Hospitals and Queen Elizabeth Hospital Birmingham
Dr Alistair Lewthwaite Consultant Neurologist Dudley Group of Hospitals and Queen Elizabeth Hospital Birmingham The Dudley PD disease team Dr Alistair Lewthwaite consultant neurologist Dr Shams Duja consultant
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationSummary of Patient < 3y at Visit 11 (90 months)
Summary of Patient < 3y at 11 (90 months) Clinician Scoring Page Direct online data entry available? Medication 378 Yes BPW 382 Yes Diagnostic Features 383 Yes UPDRS Clinician 388 Yes CISI-PD 397 Yes MoCA
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationShared Care Agreement Apomorphine For use in Parkinson s Disease
Shared Care Agreement Apomorphine For use in Parkinson s Disease This shared care agreement outlines suggested ways in which the prescribing responsibilities can be shared between the specialist and GP.
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationDrugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationFinal Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK
Final Appraisal Report Ropinirole prolonged-release (Requip XL ) for the treatment of idiopathic Parkinson s disease GlaxoSmithKline UK Advice No: 1409 August 2009 Recommendation of AWMSG Ropinirole prolonged-release
More informationB Kessel - BGS Aut 2009
www.bgsmds.org.uk www.bgsmdslive.org/ Fifth British Geriatrics Society Movement Disorders Section Award medical, nursing and therapy students are invited to submit an essay title can we change outcomes
More informationDrug treatment of early Parkinson s disease (motor symptoms)
5 Drug treatment of early Parkinson s disease (motor symptoms) 5.1 When should treatment be started for a patient with Parkinson s disease? 67 5.2 Are there guidelines for the treatment of Parkinson s
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPatient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationIntervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist
Intervention Study 2016 West ISD Gillian Ritchie Clinical Pharmacist Introduction Annual data collection Two weeks All Medicines Management Team interventions Details recorded Classified by type Outcomes
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationSHARED CARE PRESCRIBING GUIDELINE. TOLCAPONE for the Treatment of IDIOPATHIC PARKISON S DISEASE.
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex
More informationMedicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationShared Care Guideline
Shared Care Guideline Rotigotine Executive Summary Indication: Parkinson s disease, either alone or as an adjunct to co-beneldopa or co-careldopa. Patient Group: Patients with early-stage idiopathic Parkinson
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex
More informationClinical Trial Results Posting
RD..3.2 V1. Page/Seite 1 of/von 5 CT Registry ID#: NCT2428 (ClinicalTrials.gov Identifier number) These results are supplied for informational purposes only. Prescribing decisions should be made based
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationMADOPAR 100 mg/25 mg Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER MADOPAR 100 mg/25 mg Tablets LEVODOPA AND BENZERAZIDE (AS HYDROCHLORIDE) This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationParkinson s disease: diagnosis and current management
n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationPL CE LIVE July 2015 Forum
July 2015 PL CE LIVE Rachel Maynard, PharmD Associate Editor Pharmacist s Letter/Pharmacy Technician s Letter CE Information Pharmacist's Letter / Therapeutic Research Center is accredited by the Accreditation
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More information9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations
Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationPDL Class: Parkinson s Drugs
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review: September 2013 Date of Last Review:
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Parkinson s disease affects individuals globally (WHO 2006). It is the most common serious movement disorder, including speech
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationESSENTIAL CARE AFTER AN IN-PATIENT FALL
ESSENTIAL CARE AFTER AN IN-PATIENT FALL In line with the National Patient Safety Agency Rapid Response Report (NPSA/2011/RRR001): Essential care after an inpatient fall, in caring for a patient who has
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More information